Ascendis Pharma A (ASND) Receivables - Other (2016 - 2025)
Ascendis Pharma A (ASND) has disclosed Receivables - Other for 10 consecutive years, with $17.0 million as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 69.25% to $17.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Dec 2025, up 69.25% year-over-year, with the annual reading at $17.0 million for FY2025, 69.25% up from the prior year.
- Receivables - Other hit $17.0 million in Q4 2025 for Ascendis Pharma A, up from $10.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $23.0 million in Q4 2021 to a low of $10.0 million in Q4 2024.
- Historically, Receivables - Other has averaged $16.7 million across 5 years, with a median of $17.0 million in 2025.
- Biggest five-year swings in Receivables - Other: soared 177.11% in 2021 and later crashed 51.19% in 2024.
- Year by year, Receivables - Other stood at $23.0 million in 2021, then crashed by 43.04% to $13.1 million in 2022, then skyrocketed by 56.93% to $20.5 million in 2023, then plummeted by 51.19% to $10.0 million in 2024, then skyrocketed by 69.25% to $17.0 million in 2025.
- Business Quant data shows Receivables - Other for ASND at $17.0 million in Q4 2025, $10.0 million in Q4 2024, and $20.5 million in Q4 2023.